Volume 6, Supplement 9SupplementRole of Primary Care Clinicians in the Diagnosis and Treatment of LUTS and BPHLouis KuritzkyLower urinary tract symptoms5-reductase inhibitorsBenign prostatichyperplasiaDihydrotestosteronePrimary care clinicians
Volume 7, Number 4Meeting ReviewsBest of the SIU Meeting on Prostatic DiseaseMeeting ReviewJ Curtis NickelProstate cancerLower urinary tract symptomsProstate-specific antigenErectile dysfunctionProstatitisBenign prostatichyperplasiaProstate Cancer Prevention Trial
Volume 7, Supplement 4Review ArticlesA Comparison of Varying a-Blockers and Other Pharmacotherapy Options for Lower Urinary Tract SymptomsChristopher R ChappleTamsulosinAlfuzosinBlockersBenign prostatichyperplasiaFinasteride
Volume 10, Number 2Review ArticlesThe QT Interval and Selection of Alpha-Blockers for Benign Prostatic HyperplasiaTreatment UpdateHerbert LeporNorman E LeporLawrence A HillRichard G TrohmanThe QT interval is the electrocardiographic manifestation of ventricular depolarization and repolarization. Drug-induced long QT syndrome is characterized by acquired, corrected QT (QTc) interval prolongation that is associated with increased risk of torsade de pointes. Every physician must recognize if the drugs he or she prescribes prolongs the QTc interval, especially if the drug is prescribed for a chronic condition in older patients who are on polypharmacy. The evolution of alpha-blockers for the treatment of benign prostatic hyperplasia has allowed the development of drugs that are easier to administer and better tolerated. Because alpha-blockers generally have equivalent efficacy, this class of drugs is typically differentiated by safety and side effects. Studies suggest that alpha-blockers may vary in regard to their effect on the QT interval, and, therefore, on their predisposition to cause potentially life-threatening ventricular arrhythmias. [Rev Urol. 2008;10(2):85-91]BlockersBenign prostatichyperplasiaDrug-induced long QT syndromeTorsade de pointes
Volume 11, Supplement 1Review ArticlesMedical Management of Lower Urinary Tract SymptomsAdvances in the Pharmacologic Treatment of BPHEric E LabordeKevin T McVaryLower urinary tract symptoms (LUTS) are a common complaint among aging men and are often caused by benign prostatic hyperplasia (BPH). A number of medical treatments for LUTS/BPH exist, such as α-blockers, 5α-reductase inhibitors, anticholinergics, phosphodiesterase type 5 (PDE5) inhibitors, and combination therapies. Agonist binding of the α1A-adrenergic receptor (AR), causing prostatic smooth muscle contraction, has been attributed to cause some LUTS. Therefore, medical therapy has aimed to block the α1A-AR and improve LUTS. Determining which therapy to choose must take into account individual patient factors as well as cost and patient choice.[Rev Urol. 2009;11(suppl 1):S19–S25 doi: 10.3909/riu11S1S0004]© 2009 MedReviews®, LLCLower urinary tract symptomsPhosphodiesteraseCombination therapyBlockers5-reductase inhibitorsAnticholinergicsBenign prostatichyperplasia